Abstract: Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as—prostate cancer.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: Acoustic transducer comprises an upper part (301) and a lower part (302), with a first permanent magnet (303) in the upper part (301) and a second permanent magnet (304) in the lower part (302). Similarly named magnetic poles of the first and second permanent magnets (303, 304) face each other. An upper cover (306) in the upper part (301) and a lower cover (307) in the lower part (302) comprise magnetic material and define an enclosure around the magnets (303, 304). A coil (308) creates, under influence of an electric current, dynamic magnetic forces. A separating gap (309) between edges of said upper cover (306) and lower cover (307) is directed so that it allows a relative movement of the edges of said lower cover (307) and said upper cover (306) between different positions, said positions differing in the extent to which edges coincide.

Abstract: The present invention relates to novel salts, particularly crystalline salts, of 2-(isoindolin-2-ylmethyl)-5-((1-(methyl sulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one (I) which are particularly suitable for use in the manufacture of pharmaceutical 5 compositions. Furthermore, the invention relates to pharmaceutical compositions comprising such novel salts. Compound (I) is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated cancers, such as prostate cancer and breast cancer.

Abstract: The present invention relates to novel solid forms, particularly crystalline forms, of 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)piperidin-4-yl)methoxy)-4H-pyran-4-one (I). Compound (I) is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated cancers, such as prostate cancer and breast cancer.

Abstract: The present invention relates to compounds of formula (I) and (II) and pharmaceutically acceptable salts thereof. The compounds of formula (I) or (II) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: The present disclosure relates to an improved process for the preparation of isochroman structured alpha2A adrenoceptor agonist, namely 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole of formula (I) and a pharmaceutically acceptable salts thereof, such as 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole hydrogensulfate of formula (Ia), and to a novel intermediate compound used in the process, namely N-(2-aminoethyl)-5-methoxyisochroman-1-carboxamide monohydrate of formula (V). Alpha2A agonists are useful in the treatment of anxiety, and for use as a sedative or analgesic agent, and other diseases where alpha2A agonism is desired.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: The present disclosure relates to an improved process for the preparation of isochroman structured alpha2A adrenoceptor agonist, namely 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole of formula (I) and a pharmaceutically acceptable salts thereof, such as 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole hydrogensulfate of formula (Ia), and to a novel intermediate compound used in the process, namely N-(2-aminoethyl)-5-methoxyisochroman-1-carboxamide monohydrate of formula (V). Alpha2A agonists are useful in the treatment of anxiety, and for use as a sedative or analgesic agent, and other diseases where alpha2A agonism is desired.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

Abstract: A mining vehicle including a movable carrier, at least one boom having a plurality of boom joints, several boom actuators for moving the boom in different positions, at least one mining work device being arranged at a distal portion of the boom, and at least one control unit for controlling the position of at least one of the boom and the mining work device. The mining vehicle further including observing device for obtaining information indicative of a position of at least one of the boom and the mining work device in which collision to an obstacle can be avoided. The control unit is configured to control the position of at least one of the boom and the mining work device in response to the obtained information to avoid hitting the obstacle when the mining vehicle moves.

Abstract: A mining vehicle including a movable carrier, at least one boom having a plurality of boom joints, several boom actuators for moving the boom in different positions, at least one mining work device being arranged at a distal portion of the boom, and at least one control unit for controlling the position of at least one of the boom and the mining work device. The mining vehicle further including observing means for obtaining information indicative of a position of at least one of the boom and the mining work device in which collision to an obstacle can be avoided. The control unit is configured to control the position of at least one of the boom and the mining work device in response to the obtained information to avoid hitting the obstacle when the mining vehicle moves.

Abstract: Compounds of formula (I), wherein X and R1-R6, are as defined in the claims, exhibit alpha2 agonistic activity and thus are useful as alpha2 agonists, especially as alpha2A agonists. Methods of use of said compounds are also provided.

Abstract: Compounds of formula (I), wherein X and R1-R6, are as defined in the claims, exhibit alpha2 agonistic activity and thus are useful as alpha2 agonists, especially as alpha2A agonists. Methods of use of said compounds are also provided.

Abstract: This invention relates to method for presenting at least a part of a page, comprising at least partially dividing at least one page into a plurality of areas, presenting said plurality of areas in a first representation, making at least one area of said plurality of areas an active area, and in response to a user operation on said at least one active area, presenting at least one of said at least one active areas in a second representation. Said at least one page may be a Hypertext Markup Language HTML page, or a page of a text document, and said display may be integrated in a portable electronic device. The invention further relates to a device, a system, a computer program and a computer program product.

Abstract: The invention relates to network connection management, wherein user confirmations are queried for implementing operations requiring a network connection. According to the invention the user confirmation are queried variantly depending on the initiator of the operation. The invention relates to a devices for browsing the network and to a computer program product.

Abstract: The invention relates to a method and an apparatus of requesting a service from a communications network. In the method the following steps are to performed: generating an objective statement in a user equipment; communicating the objective statement from the user equipment to a mediator unit; comparing the objective statement to a list of objective statements in the mediator unit; establishing the service based at least partly on the comparison; and providing the service to the user of the user equipment.